Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease

Gut

Volumn 50, Issue 2, 2002, Pages 196-200

  Bauditz, Juergen ^a   Wedel, S ^a   Lochs, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG INDUCED DISEASE; FATIGUE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SEDATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; COLITIS; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FATIGUE; FEMALE; HUMANS; INTERLEUKIN-12; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MONOCYTES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036155980     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.2.196     Document Type: Article

References (36)

1. Enhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn's disease
2. Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
3. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
4. Cytokine messenger RNA profiles in inflammatory bowel disease detected by polymerase chain reaction amplification
5. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
6. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric antibody (cA2)
7. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease
8. Inflammatory properties of recombinant tumor necrosis in rabbit skin in vivo
9. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection
10. Modulation of endothelial cell hemostatic properties by TNF: Insights into the role of endothelium in the host response to inflammatory stimuli
11. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor
12. Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability
13. Serum concentrations of release tumor necrosis factor-alpha in childhood chronic inflammatory bowel disease
14. Tumor necrosis factor alpha in stool as a marker of intestinal inflammation
15. Thalidomide in Crohn's disease
16. Thalidome and congenital abnormalities
17. Thalidomide selectively inhibits tumor necosis factor alpha production by stimulated human monocytes
18. Chronic cutaneous lupus erythematosus treated with thalidomide
19. Thalidomide for the treatment of chronic graft-versus-host disease
20. Treatment of refractory rheumatoid arthritis - The thalidomide experience
21. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial
22. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve steroid dependent chronic active Crohn's disease in a pilot study
23. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
24. Inhibition of IL-12 production by thalidomide
25. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
26. An open-label pilot study of low-dose thalidomide in chronically-active, steroid-dependent Crohn's disease
27. European cooperative Crohn's disease study (ECCDS): Results of drug treatment
28. Coated mesalazine (5-aminosalicyc acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial
29. Development and validation of an endoscopic index of the severity for Crohn's disease: A prospective, multicentre study
30. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions
31. Upregulation of the IL-12 receptor β2 beta unit chain in Crohn's disease
32. Antibodies to interleukin 12 abrogate established experimental colitis in mice
33. Thalidomide: A novel therapy for microsporidiosis
34. An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
35. CC 3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production
36. Thalidomide analogue CC 1069 inhibits development of rat adjuvant arthritis